A mini-review in Frontiers in Medical Technology argued that sepsis diagnosis remains bottlenecked not by a lack of biomarker candidates but by translation into certified in vitro tests that fit emergency workflows. The authors—Erika P. Plata-Menchaca, Enrique Hernández-Jiménez, and collaborators—reframe biomarker evaluation around concrete clinical decisions such as starting or stopping antibiotics, admitting patients, and monitoring severity. The review emphasizes conventional markers like procalcitonin, CRP, IL-6, and lactate while highlighting their biological non-specificity and confounding factors in real-world settings such as surgery, trauma, and renal dysfunction. It also aligns with the 2026 Surviving Sepsis Campaign guidance emphasizing early recognition and responsible antimicrobial de-escalation. Separately, new ML work combining brain MRI segmentation with severity scores reported strong discrimination for sepsis-associated encephalopathy, supporting the broader push toward risk stratification tools that can be used rapidly at the bedside. For biotech and medtech teams, the central message is operational: evidence must clear regulatory and workflow hurdles to reach the emergency pathway intact.